Viagra Professional Wikipedia

The efficacy, safety, and tolerability of sildenafil in the treatment of men with ED have been demonstrated in numerous studies of 1-year duration or less. For example, 1,358 men with ED completed 1 of 4 double-blind trials and continued with open-label sildenafil treatment in extension studies for a total treatment duration of approximately 1 year (Morales et al 1998; Steers et al 2001). In the current study, 979 of these men subsequently received up to 4 more years of open-label, flexible-dose (25, 50, and 100 mg) sildenafil. Preliminary (3-year) results were reported previously (Carson et al 2002; Padma-Nathan et al 2002), and we now present the final data. The population included patients with ED of organic and psychogenic etiology and typical concomitant medical conditions for this population (ie, hypertension, diabetes, hyperlipidemia, and a history of ischemic heart disease). Our objective was to assess the long-term safety and effectiveness of sildenafil treatment in men with ED.

Conclusions

James McMurray, Robert Feldman, and Stephen Auerbach are study investigators for Pfizer Inc. James McMurray has no relevant financial interest in the manuscript (ie, honoraria, stock ownership or options, expert testimony, grants received or pending, patents, royalties, or other). Robert Feldman has consulted on drug development for Pfizer Inc in the past, received honoraria for lectures, and owns Pfizer Inc stock. He has no other relevant financial interest in the manuscript (ie, expert testimony, grants received or pending, patents, royalties, or other). Stephen Auerbach has participated on advisory boards and received honoraria for lectures for Pfizer Inc, Eli Lilly and Company, GSK and Schering-Plough Corporation, Threshold Pharmaceuticals, and Indevus Pharmaceuticals. He has received grants and/or has grants pending from the above companies, Watson Pharmaceuticals, and PPD (Pharmaceutical Product Development). Herb deRiesthal is an employee of Pfizer Inc, and Neal Wilson is a former employee of Pfizer Inc.

Baseline characteristics of the 979 men

The recommended dose of Sildenafil Actavis is 50 mg taken as needed about one hour before sexual activity. If Sildenafil Actavis is taken with food, the onset of activity may be delayed compared with taking Sildenafil Actavis without food. The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects. Patients with liver problems or severe kidney problems should start treatment with the 25-mg dose. The maximum recommended dosing frequency is one tablet per day.

La gestión ambiental local constituye un proceso transversal y permanente relacionado con las instancias que involucran la toma de decisiones de índole ambiental, la apropiación y el uso de los recursos naturales y el desarrollo sustentable de la comuna.

Despite a preferred sildenafil dose of 100 mg (the highest recommended dose) in more than 88% of the men, treatment-related cardiovascular adverse events necessitating changes in dosing or temporary or permanent discontinuation were limited to one case each of mild palpitations and tachycardia and 5 cases of flushing. There were no treatment-related acute myocardial infarctions or other serious adverse events. Only 1.1% of participants discontinued treatment over 4 years because of treatment-related adverse events, which were most frequently dyspepsia, rhinitis, and headache. In comparison, treatment-related adverse events were responsible for discontinuation by 1.2% of men treated with sildenafil 100 mg in 6-month, double-blind, placebo-controlled trials (Morales et al 1998) and by 2% of 1008 men enrolled in 36-week or 52-week, open-label extension studies (Steers et al 2001). Adverse events were responsible for similarly low rates of discontinuation in clinical practice studies of varying duration conducted worldwide; in California 2.7% of 74 men discontinued (Marks et al 1999), in Brazil none of 256 men discontinued (Moreira et al 2000), and in China none of 1,290 men discontinued (Jiann et al 2003). Among 22,471 men treated with sildenafil in general practice in the UK, headache was the most frequently reported treatment-related adverse event and was cited as the reason for discontinuation in 0.3% of men (Boshier et al 2004).

Para la Ilustre Municipalidad de Valdivia es un importante desafío continuar avanzando en el camino de la certificación ambiental municipal, razón por lo cual se encuentra implementando y desarrollando líneas estratégicas enfocadas en lograr una comuna sustentable y con mejor calidad de vida para sus habitantes.

In March 1998, the US Food and Drug Administration (FDA) approved sildenafil citrate (Viagra ® , Pfizer Inc, New York, NY, USA) for the treatment of erectile dysfunction (ED) (FDA 1998). As of December 2005, more than 27 million men worldwide had received sildenafil for treatment of ED, including an estimated 17 million men in the US (Data on file, Pfizer Inc, New York, NY). Thus, the long-term safety and effectiveness of sildenafil can now be evaluated in men who have been taking the drug for several years.

a For the satisfaction analyses, N is equal to the number of men who answered the satisfaction question. For the respective sexual activity analyses, N is equal to the number of men who answered the satisfaction question affirmatively and answered the sexual activity question.

The European Commission granted a marketing authorisation valid throughout the European Union for Sildenafil Actavis on 10 December 2009.

In arriving at the sentences, Judge Hittner considered the fact that the illegally imported counterfeit drugs did not contain the correct medication indicated on the labelling and could cause harm to unsuspecting consumers of the pills.

Sildenafil Actavis is a ‘generic medicine’. This means that Sildenafil Actavis is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Viagra.

Methods

Sildenafil Actavis is a medicine that contains the active substance sildenafil. It is available as tablets (25, 50 and 100 mg).

The active ingredient in Sildenafil Actavis, sildenafil, belongs to a group of medicines called phosphodiesterase-type-5 (PDE5) inhibitors. It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax. This allows blood to flow into the corpora, producing the erection. By blocking the breakdown of cGMP, Sildenafil Actavis restores erectile function. Sexual stimulation is still needed to produce an erection.

Overall, 979 men initially agreed to participate in the study, most of whom were white (89%) and whose mean age was 58 years ( Table 1 ). The duration of the double-blind trials plus initial open-label extension was 0.9 to 1.2 years (48–60 weeks). Median duration of participation in the open-label, long-term extension study was 4 years, the median number of doses taken was 420 (range, 1–1469) ( Figure 2 ), and the preferred dose was 100 mg in more than 88% of the men. The retention rate was 84% (818/979) the first year, 75% (731/979) the second year, and 66% (648/979) the third year; the entire 4-year extension study was completed by 584 of the initial 979 men (60%) ( Figure 1 ). Reasons for discontinuation included loss of interest in participation in a clinical study, loss of sexual partner, loss to follow-up, ability to afford sildenafil after approval (thus, no longer needing to participate in a clinical study to obtain the medication), insufficient clinical response, and adverse events.

Usage of flexible-dose (25, 50, and 100 mg) sildenafil over 2–1561 days by the 979 participants who entered the study.

The most common sexual dysfunctions in men include lack of interest, premature ejaculation and erectile dysfunction. The latter affects 52% of men between the ages of 40 and 70, including mild, moderate and complete forms of ED.

Comité Ambiental Municipal (Comité Valdivia Ciudad Verde)

b Because serious adverse events are collected for a longer period (30 days after the completion of treatment) than adverse events in general, numbers of events may vary between these 2 databases.